Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VentriPoint DiagnosticsVPTDF Revenue per Share is $0.00 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 756 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks worse than 132275% on this metric.
VentriPoint Diagnostics's revenue per share for the
three
months ended in Dec. 2025 was $0.00.
VentriPoint Diagnostics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for VentriPoint Diagnostics's Revenue per Share or its related term are showing as below:
During the past 13 years, VentriPoint Diagnostics's highest 3-Year average Revenue Per Share Growth Rate was 17.00% per year. The lowest was -59.50% per year. And the median was -36.10% per year.
VPTDF's 3-Year Revenue Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.7 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
VentriPoint Diagnostics Revenue per Share Related Terms
VentriPoint Diagnostics Revenue per Share Historical Data
* Premium members only.
The historical data trend for VentriPoint Diagnostics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VPTDF vs ABT, SYK, MDT: Revenue per Share Comparison
For the Medical Devices subindustry, VentriPoint Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's PS Ratio distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's PS Ratio falls into.
VentriPoint Diagnostics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
VentriPoint Diagnostics's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a Revenue per Share of $0.00 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 756 companies in the Medical Devices & Instruments industry.
Is VentriPoint Diagnostics' Revenue per Share too high?
VentriPoint Diagnostics' current Revenue per Share is $0.00. Based on the distribution chart, VentriPoint Diagnostics ranks #999999 out of 756 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does VentriPoint Diagnostics' Revenue per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #999999 out of 756 companies for Revenue per Share. This places VentriPoint Diagnostics in the lower half of its industry. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Revenue per Share of $0.00. The current Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Revenue per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
